^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SAIT101 (rituximab biosimilar)

    i
    Other names: SAIT101, SAIT-101
    Associations

    News

    Trials
    Company:
    Archigen Biotech
    Drug class:
    CD20 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    RAMO-2: A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma (clinicaltrials.gov)
    P3, N=315, Completed, Archigen Biotech Limited | Active, not recruiting --> Completed | Trial completion date: May 2020 --> Jan 2020
    Clinical • Trial completion • Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • SAIT101 (rituximab biosimilar)